NCT04797182

Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma

Conditions

• Thrombocytopenia
• Cytarabine Causing Adverse Effects in Therapeutic Use
• Lymphoma

Interventions

Type	Name	Description
DRUG	avatrombopag	avatrombopag,60 mg/d,po

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-04-01
• Completion: 2023-07-01
• First posted: 2021-03-15
• Last updated: 2021-03-15

Locations

1 site across 1 country: China